Objective: To evaluate the effect of fish oil supplementation on pregnancy outcomes in mother and newborn. Methods: This randomized, triple-blind, placebocontrolled trial was conducted on 150 pregnant women aged 18-35 years from Feburary 2014 to April 2015 in Tabriz, Iran. Participants were assigned to receive either 1000 mg fish oil supplements containing 180 mg eicosapentaenoic acid (EPA) and 120 mg docosahexanoic acid or placebo from week 20 of gestation to birth. The primary outcome measure was birth weight. Gestational duration, preterm labor low birth weight (LBW), length, head circumference, and maternal serum docosahexaenoic acid (DHA) and EPA level at 35-37 weeks were also examined. The statistical analysis was on an intention-to-treat basis. Results: Demographic characteristics were similar in both groups (P > 0.05). The mean (SD) birth weight values in the fish oil and placebo groups were 3256 (362) g and 3172 (447) g, respectively (adjusted mean difference (MD) = 84.1 g, 95% confidence interval [CI] = − 24.8 to 193.2). Five (7.6%) neonates in the placebo versus no case in the fish oil group were born with LBW (P = 0.02). The rate of preterm labor was lower in the fish oil group (adjusted OR = 0.74, 95% CI = 0.16-3.42). However, there were no statistically significant differences in the maternal outcomes (P > 0.05) with the exception of the proportion of maternal serum DHA fatty acid at 35-37 weeks (P < 0.001). Conclusion: Although low dose fish oil supplementation increased birth weight, its effect was not statistically significant. The frequency of LBW was significantly reduced in the intervention group, but the observed reduction needs to be confirmed in future larger investigations using different doses of omega-3.
Introduction
Omega-3 fatty acids are essential unsaturated long-chain fatty acids that are necessary for proper health and growth. Fish oils contain long-chain fatty acids of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) [1] . Fish oil capsules are relatively free of mercury and other harmful compounds such as polychlorinated biphenyls and can be used to increase the omega-3 intake [2] . The use of fish oil supplements during pregnancy has been studied as a potential strategy to prevent preterm birth and preeclampsia as well as to increase birth weight [3] [4] [5] . Theories supporting birth results of this study were developed based on the observations of heavy weight at birth and long pregnancy in societies with high fish consumption [6, 7] .
DHA and EPA fatty acids prevent the contraction of blood vessels [8] . Additional amounts of EPA in the diet lead to a decreased production of proinflammatory eicosanoids of PGE2 and PGF2α and an increased production of prostacyclin (PGI2), which increases myometrium relaxation [9, 10] . These fish oil components may delay labor and, thereby, potentially increase the length of pregnancy and birth weight by preventing the production of prostaglandins that cause cervix ripeness [11] . Studies on these mechanisms and their potential health benefits for mothers and newborns led to inconsistent results [3, 4, 12, 13] . A systematic review showed that although there is no sufficient evidence to support routine supplementation during pregnancy to reduce the risk of preeclampsia, preterm labor, or low birth weight (LBW), pregnant women can take fish oil supplements during pregnancy to increase the length of pregnancy [11] . According to the World Health Organization, fish oil may avoid pregnancy complications but no sufficient evidence is available to support routine fish oil supplementation [14] .
Most randomized clinical trials on prenatal fish oil supplementation have been conducted in high-income countries. Therefore, findings may not be generalizable to populations of low-and middle-income countries [15] . Annual per capita fish consumptions in Iran and throughout the world reported to be 7 and 18 kg, respectively. However, this figure is 4.5 kg in East Azerbaijan Province, Iran [16] . Therefore, the present trial was aimed to evaluate the effect of fish oil supplementation on pregnancy outcomes for both mother and newborn.
Materials and methods

Study type and subjects
This randomized, triple-blind, placebo-controlled clinical trial with two parallel arms was conducted in Tabriz, Iran. The inclusion criteria included 18-to 35-year-old women who are in their first to fifth pregnancy, who have family health records in public health centers, who are willing to participate in the study, who are literate and able to answer the questions, who are in weeks 16-20 of pregnancy, who have singleton pregnancy, and who have a phone number. The exclusion criteria were as follows: willingness to relocate in the next 6 months; women with vaginal hemorrhage, placenta previa, and abruption and cerclage in the current pregnancy; history of infertility and premature labor; any history of allergy to fish or fish products and gelatin; previous underlying diseases according to the mother, such as cardiovascular, renal, gastrointestinal, respiratory, and autoimmune diseases; positive impaired glucose tolerance in the current pregnancy; epilepsy; underlying hypertension, psychiatric disorders, hyperlipidemia, etc. and taking medications due to any of these conditions; mothers who consumed more than two servings of fish per week; smokers or drug users; presence of bleeding disorders; taking anticoagulants; body mass index (BMI) of more than 30 kg/m 2 ; and participating in another intervention.
Sample size was calculated based on birth weight that was the primary outcome. According to one study in Iran [17] , by considering α = 0.05 and β = 0.1, m1 = 3282 (mean birth weight in the control group) and m2 = 3446 (considering at least 5% increase through our intervention), and Sd1 = 353 and Sd2 = 249, sample size was estimated as 61 for each group. Seventy-five subjects were accounted by considering approximately 20% dropout.
Sampling
After obtaining permission from the Ethics Committee of Research and Technology Deputy of Tabriz University of Medical Sciences (no. 92141) and registration on the Iranian registry of clinical trials website (IRCT2013100914957N1), five public health centers of Tabriz with different sociocultural status areas and highest number of referred patients were selected. All eligible women were invited to participate at the study, and details of the study including its objectives, probable risks, and benefits of participating in the voluntary nature of the study were explained. Participation in the study was proposed to them in the first visit at 6-10 weeks of pregnancy. The mentioned matters were emphasized in the second visit at 16-20 weeks, and then women who gave consent for participation in the study were recruited into the study. In this research, 652 women were assessed for eligibility; 502 were excluded because 192 (29.4%) of the women did not meet the eligibility criteria and 310 (47.5%) of them declined to participate. Finally, 150 women participated, and before week 20 of gestation, they were randomly allocated into the fish oil or placebo group. Basic information was completed, and daily consumption of capsules as well as checklists of possible events were given to them. Content validity was used to determine the validity of the questionnaires.
Randomization and intervention
Pregnant women were randomly assigned into one of the two groups (the group receiving fish oil capsule supplements and the group receiving placebo) using computer randomization scheme. Allocation sequence was determined using random permuted blocks with sizes 4 and 6 and an allocation ratio of 1 : 1. The dose of fish oil capsules was 1000 mg (containing 120 mg of DHA, 180 mg of EPA, and 400 mg of ALA) once a day. The placebo capsules had the same shape, size, and weight and contained 1000 mg of liquid paraffin. Both medications were produced by Zahravi Pharmaceutical Company, Tabriz, Iran. One capsule was consumed per day starting from the end of the 20th week of pregnancy until labor with a duration of approximately 20 weeks (140 capsules). The capsules were placed inside sequentially numbered opaque sealed containers. Two packs containing 70 capsules for a 10-week usage were prepared for each participant. The two packs were placed in a big container numbered sequentially. The sequence generation and preparations were done by a person not involved in the study to conceal allocation and maintain blinding. Researchers who were care providers enrolled participants at 6-10 weeks of gestation and assigned them into the groups after obtaining informed consent at 16-20 weeks. The first pack was delivered at the second visit (weeks [16] [17] [18] [19] [20] , whereas the second pack was delivered at the third visit (weeks 26-30) after making sure from their consumption of the previous medication by collecting the consumed medication blisters and daily drug record checklist. To ensure acceptance and medication use, the remaining consumed medication blisters were also collected at the end of intervention. Participants were asked to use the medication completely, and they also were requested not to forget to take any medications. Besides, to ensure the proper use of medication, follow-ups were conducted via phone calls twice at weeks of 24 and 34. Stratified sampling was carried out in terms of pregnancy number (first, second, or more) and recruitment centers. Numbers 1-75 were assigned to the nulliparous women, whereas numbers 76-150 were assigned to the multiparous women. Thirty sequenced envelopes, 15 for nulliparus and 15 for multiparous women, were considered for every five health centers. Hence, sequenced envelopes numbered 1-15 and 76-90 were allocated to health center 1, and the process continued for other health centers. Training and implementation of the protocol were standardized across sites by holding training sessions attended by all researchers before intervention. The head researcher as a trainer and coordinator monitored the whole process of RCT by supervising the research deputy of Tabriz University of Medical Sciences and collected data. Participants, researchers, and those assessing outcomes were blinded after assignment to the interventions in this study.
Assessment of study variables
Three milliliters of fasting blood was drawn from the subjects at the baseline. The samples were immediately centrifuged (Hettich, Universal 320, Germany) at 3500 rpm for 10 min to remove serum.
The blood samples were sent to the laboratory at the Faculty of Medicine, Tabriz, Iran, for fatty acid analysis. To measure the serum phospholipids levels of DHA and EPA, lipids were extracted and analyzed for fatty acid composition as described previously (18) . Briefly, serum phospholipids fractions were separated by thin layer chromatography method. Fatty acid methyl ester derivatives formed from isolated serum phospholipids were separated on a 60 × 0.25-mm Teknokroma TR CN100 column using a Buck Scientific model 610 gas chromatograph (SRI Instruments, Torrance, USA) equipped with a split injector and a flame ionization detector. Helium was used as the carrier gas. The oven temperature was increased from 170°C to 210°C at the rate of 1°C/min and then maintained stable for 45 min. Tridecanoic acid (13:0) was used as the internal standard and peak retention times were identified by injecting known standards (Sigma chemicals, USA). Data were analyzed with Peak simple software (SRI instrument) and the results were expressed as percentage of total FAs.
Height and weight before pregnancy and hemoglobin and hematocrit at weeks of 6-10 and 26-30 of pregnancy were recorded using mothers' records according to mothers' routine integrated care. Maternal and neonatal outcomes (duration of pregnancy, preterm labor maternal weight gain, preeclampsia, anthropometric measurement, and LBW) were completed after labor at the first newborn visit using subjects' records and interviews. The gestational age was determined using valid mothers' LMP, and if it was not valid or forgotten, it was determined using first trimester ultrasound. Preterm labor that was defined as labor occurred between 20 and 37 weeks of pregnancy. Maternal weight was measured at each visit without wearing shoes and with minimal clothing using a scale (Seca, Germany). The proper functioning of the scale was frequently evaluated using a 500-g control weight. Maternal weight was recorded in the mothers' weight gain table in the prenatal care forms, and the weight gain was calculated. Appropriate pattern of weight gain during pregnancy was determined based on the weight gain charts dedicated to women with underweight, normal, and overweight BMI. The neonatal weight was measured at birth in the reception room with minimal clothing using a lever scale (Seca, Germany). The newborn's height was measured in the supine position using a stadiometer table without shoes and hats. The neonatal head circumference was measured using a tape measure (Laica, Italy) without wearing any clothing around the head from the occipital prominence to the forehead in the newborn reception room.
LBW was defined as birth weight less than 2500 g. The gestational age was calculated using valid LMP or using early ultrasound in the case of uncertainty of LMP.
Mercury-free fish oil supplements were purchased from the pharmaceutical company. The cold vapor atomic-absorption spectrometry method was used to reassure being mercury free of the fish oil. No mercury was found in the oils after three measurements from three different samples.
Statistical analysis
The Kolmogorov-Smirnov test was used to examine the normal distribution of quantitative variables and approved. The analyses were done based on an intention-to-treat approach. Comparisons between two groups in general characteristics were made using the independent t-test for continuous variables. For categorical variables, χ 2 and Fisher's exact test were used. Analysis of covariance (ANCOVA) was used to find differences between two groups in terms of maternal and neonatal continuous variables adjusted for the preinterventional levels of hemoglobin and hematocrit, parity of mother, recruitment center, and gender of neonates. Binary logestic regression was conducted to determine differences between two groups for categorical maternal and neonatal variables adjusted for parity of mothers and gender of neonates. P-value less than 0.05 was considered as statistically significant. All statistical analyses were done using the Statistical Package for Social Science version 21.
Results
The participants were recruited from February to November 2014 and followed-up until April 2015. Only one subject in the placebo group discontinued consuming capsules because of nausea, but because the analysis was on an intention-to-treat basis, all 150 participants were included in the final analysis (Figure 1 ). Irregular uses of capsules were reported in two subjects (2.6%) of each group. In others (97.4%), all capsules were taken during the whole intervention. None of the participants had history of gestational diabetes, preeclampsia, and eclampsia in the previous pregnancies. There were no significant differences between two groups in terms of socio demographic characteristics, mode of delivery, cause of cesarean section, and baseline EPA and DHA serum levels (P > 0.05) ( Table 1) .
According to medical records, one participant (1.4%) in the fish oil group and three subjects (4%) in the placebo group had excessive hemorrhage and did not require blood transfusions. There were no statistically significant differences in the baseline hemoglobin and hematocrit serum levels between two groups.
The mean (SD) birth weights were 3256 (362) g in the fish oil group and 3172 (447) g in the placebo group (adjusted mean difference (MD) = 84.1, 95% CI = − 24.8 to 193.2). There were no significant differences between the groups in neonatal anthropometric indices. Five neonates (6.7%) in the placebo group compared with no one in the fish oil group were born with LBW (P = 0.02). On the basis of the results, 15 pregnant women should receive the fish oil supplements to prevent LBW in one neonate [number needed to treat (NNT): 15; absolute risk reduction: 0.067 (0.005-0.147)].
Three neonates (1.4%) in the fish oil group and four neonates (4.5%) in the placebo group were premature, but this difference was not significant (adjusted OR = 0.76, 95% CI = 0.16 to 3.62) ( Table 2 ). Only one neonatal death (4.1%) occurred in the placebo group at the first day because of congenital abnormality.
The mean (SD) duration of pregnancy in the fish oil and placebo groups was 274.8 (9.5) and 274.6 (10.9) days, respectively (adjusted MD = 0.20, 95% CI = − 3.53 to 3.93). Preterm labor was observed in three participants (4.1%) in the fish oil group and four participants (5.4%) in the placebo group (adjusted OR = 0.76, 95% CI = 0.16 to 3.62). There was no preterm birth earlier than 34 weeks in two groups. The mean (SD) weight gain was 12.2 (3.1) kg in the intervention group and 11.9 (4.0) kg in the control group (adjusted MD = 0.25, 95% CI = − 0.97 to 1.47). The weight gain patterns in 52.7% of the participants in the fish oil group versus 43.8% in placebo group were appropriate for BMI (adjusted OR = 1.59, 95% CI = 0.80 to 3.15). Hemoglobin and hematocrit (26-30 weeks) adjusted for baseline values were similar in two groups. There were no statistically significant differences between two groups in terms of maternal outcomes (P > 0.05) ( Table 3) . None of the participants in both groups were diagnosed with preeclampsia.
Supplementation with fish oil significantly increased the mean serum percentage of DHA fatty acid at 35-37 weeks (0.57 ± 0.2 vs. 0.39 ± 0.2 in the placebo group) (adjusted MD = 0.15, 95% CI = 0.08 to 0.23). The mean (SD) serum percentage of EPA fatty acid at 35-37 weeks was not different between groups (0.25 ± 0.1 vs. 0.23 ± 0.1 in the placebo group) (adjusted MD = 0.04, 95% CI = − 0.01 to 0.08) as reported in a published study [18] .
The reported side effects were as follows: nausea in 7 participants (9.3%) in the fish oil group and 10 participants (13.3%) in the placebo group, unpleasant taste in 6 participants (8%) in the intervention group and 10 participants (13.3%) in the control group, vomiting and mild diarrhea in 1 participant (1.33%) in the fish oil group and stomach pain in 1 participant (1.33%) in the placebo group. There were no significant differences between groups (P > 0.05). These occurred mostly in the early use that did not prevent taking the capsules. Only one woman in the placebo group discontinued intervention because of continuous severe nausea. Most participants were satisfied with taking capsules in both fish oil (95%) and placebo (93.2%) groups (P > 0.05).
Discussion
Fish oil supplements with a dose of 1000 mg/d (containing 120 mg of DHA, 180 mg of EPA, and 400 mg of ALA) were consumed from week 20 of pregnancy until 1 month after labor. The mean birth weight in the fish oil group was 84 g higher than the control group, but it was not statistically significant. The frequency of newborns with LBW was 6.7% in the placebo group but not observed in the fish oil group, and the difference was statistically significant. In terms of height and head circumference, there was no significant difference between the fish oil and the placebo groups. The rate of preterm labor in the fish oil was less than the placebo group, but the difference was not statistically significant. The mean (SD) duration of pregnancy in the fish oil was slightly longer than the placebo group; however, the difference was not statistically significant.
Literature about the effects of omega-3 fatty acids on maternal outcomes is inconsistent.
In a review study conducted on the effectiveness of omega-3 supplementation in preventing repeated preterm labor, birth weight was significantly higher than the control group [19] . Larque et al. [20] also found similar results in their review. In a trial, DHA supplementation led to increased birth weight, height, and head circumference. The number of infants born before 34 weeks was also significantly less in the intervention group [21] . A review study including 1187 women indicated that birth weight was higher (71 g) in women receiving n-3 fatty acid supplements during pregnancy. The incidence of LBW was not statistically significant in this study [22] . In a clinical trial, the women receiving DHA had newborns with higher birth weight and head circumference. Researchers concluded that small amounts of DHA may improve fetal growth in a population with a low intake of DHA in baseline [4] . In a review study including six randomized controlled trials, head circumference was 0.26 cm greater than the group receiving n-3 LCPUFA supplements [23] .
The previously mentioned studies showed statistically significant increase in terms of birth weight, height, and head circumference. Although the birth weight was 84 g higher in the fish oil group in our study, this difference was insignificant. This may be due to the differences in sample size, environmental and nutritional differences between subjects, use of different doses of medication, Fisher's exact test were used. Fetal complications include malpresentation, distress, dense meconium, and macrosomia. Maternal complications include pelvic disorders and exhaustion. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid, expressed as percent of total fatty acids; SD, standard deviation. and research methodology. In our study, there was no case of birth before 34 weeks of pregnancy. The dose of fish oil supplements used in this study was relatively small; however, the frequency of LBW was significantly lower in the fish oil group.
In a review study, n-3 LCPUFA supplementation led to a moderate increase in birth weight (42 mg MD), but there was no significant difference regarding height and head circumference [24] . In another review study on use of fish oil supplements during pregnancy on 2783 women, birth weight was slightly higher (47 g MD). However, no significant difference was found in terms of birth weight, LBW, and small-for-gestational age between two groups [11] . In a trial conducted on 341 subjects (148 women receiving 1.18 g/d of DHA and 0.8 g/d of EPA versus 137 women receiving corn oil), there was no difference in terms of birth weight [25] . Other researchers in their review article concluded that there was no sufficient evidence to prove that fatty acid supplementation can reduce the risk of LBW [26] . In our study, the rate of LBW was significantly lower in the group receiving supplements.
The great amount of EPA in the diet could cause a decreased production of proinflammatory eicosanoids of PGE2 and PGF2α and an increased production of prostacyclin (PGI2), which increases myometrium relaxation [9, 10] . These fish oil components may delay labor and, thereby, potentially increase the length of pregnancy and birth weight through preventing the production of prostaglandins that cause cervix ripeness [11] . Nonetheless, in pregnancy, the actual importance of EPA may be due to its effect on mediating DHA and AA concentrations across the placenta [27] . However, the significant difference between the two groups in LBW and an increase of 84 g in birth weight in the present study could not be explained by gestational duration.
Similar to the neonatal outcomes, results reported in different studies on the effect of omega-3 fatty acids on maternal outcomes are inconsistent with the current study. The results of some clinical trials and review studies indicated that the n-3 LCPUFA supplementation during gestation increased the duration of pregnancy [11, [21] [22] [23] [24] 28] . The inconsistency of their results with our results may be due to different study environment, eligibility criteria, and supplemental dose. The use of higher doses of DHA and EPA, the larger sample size, and the use of DHA alone could explain different results. Given that low-risk women were enrolled in our study, no case of labor before week 34 of pregnancy or preeclampsia was observed in each group.
In accordance with our study, the results of other studies showed that n-3 LCPUFA supplementation during pregnancy had no effect on the duration of pregnancy [4, 12, 19, 29, 30] .
Most studies regarding the effect of omega-3 supplementation on pregnancy outcomes have been conducted in high-income countries, so the results could not be generalized to low-income countries [15] .
In our study, two-thirds of the subjects did not consume fish even once a week. In the trial conducted in Qazvin, Iran, on high risk women for preeclampsia, no significant difference in terms of duration of pregnancy was observed between groups receiving omega-3 supplement and the placebo during pregnancy. However, birth weight was significantly higher in the omega-3 group [31] . An observational study conducted in Hamadan, Iran, showed that omega-3 intake during pregnancy significantly avoids LBW, preeclampsia, and preterm labor [32] .
DHA dose in various trials ranges between 100 and 2800 mg, whereas the EPA dose in different trials ranges between 100 and 3000 mg.
This study had no loss to follow-up because the women were given the required information about the study during their first visit and also were provided with the opportunity to make a decision to participate before being recruited in this trial at 16-20 weeks of pregnancy. The necessity of regular intake of supplements was stressed in several times. A phone number was provided for 24-h contact in the event of a problem. In the case of side effects, the necessary consultation was available. Follow-ups were conducted regarding use of medications, and used blisters were collected two times. Nulliparous and multiparous women were equally allocated into two groups using the stratification method. Serum levels of DHA and EPA were examined before the intervention so that they could be adjusted if they were different. To ensure the safety of the medications, the mercury levels of fish oil supplements were evaluated.
A limitation of the present study was the impossibility of evaluating umbilical DHA and EPA fatty acids and the relatively low doses of omega-3, which was the only available dose. It is recommended to conduct a study with different and higher doses of fish oil supplementation. The umbilical fatty acid levels and their relationship with the respective outcomes can also be studied. The other limitation of this study was accounting the frequency of LBW as a secondary outcome that resulted in lower power less than 80%. Thus, this study proposes conducting further studies with larger sample size and considering low birth weight as the primary outcome. It is also recommended to perform a similar study on obese women.
Conclusion
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